Desktop version

Home arrow Health

  • Increase font
  • Decrease font

<<   CONTENTS   >>

Food Sources of Folate

Green leafy vegetables are rich sources of folate, providing the basis for its name. Citrus fruits and legumes are also excellent sources.

Leaf lettuce 1 cup 40 |ig

Kale, chopped 1 cup 19 |ig

Spinach, cooked 1 cup 263 |ig

Orange, raw 1 47 |ig

Chickpeas, cooked 1/2 cup 141 |ig


  • 1. Plaisted CS, Istfan NW. Metabolic abnormalities of obesity. Obesity Pathophysiology Psychology and Treatment. In: Blackburn GL, Kanders BS, eds. New York, NY: Chapman & Hall 1994.
  • 2. Tailleux A, Rouskas K, Pattou F, et al. Bariatric surgery, lipoprotein metabolism and cardiovascular risk. Curr Opin Lipidol2015;26:317-324.
  • 3. Kaplan NH. Hypertension and hyperinsulinemia. Prim Care 1991;18:483.
  • 4. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595.
  • 5. Feingold KR, Grunfeld C. Obesity and dyslipidemia. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., eds. Endotext [Internet]. South Dartmouth, MA:, Inc.; 2000. Available at: http://www
  • 6. Padilla N, Maraninchi M, Beliard S, et al. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans. Arterioscler Thromb Vasc Biol2014;34:2330-2337.
  • 7. Batsis JA, Miranda WR, Prasad C, et al. Effect of bariatric surgery on cardiovascular risk in elderly patients: A population-based study. Geriatr Gerontol Int 2015;16:618-624.
  • 8. Domienik-Karlowicz J, Dzikowska-Diduch O, Lisik W, et al. Shortterm cardiometabolic risk reduction after bariatric surgery. Hellanic J Cardiol 2015;56:61-65.
  • 9. Corcellas R, Daigle CR, Schauer PR. Management of endocrine diseases: Metabolic effects of bariatric surgery. Eur J Endocrinol 2016;174:R19-28.
  • 10. Morshed G, Fathy SM. Impact of post-laparoscopic sleeve gastrectomy weight loss on C-reactive protein, lipid profile and CA-125 in morbidly obese women. Wideochir Inne Tech Maloinwazyjne 2016;10:521-526.
  • 11. McLellan KCP, Wyne K, Villagomez ET, et al. Pharmacologic treatment of prediabetes. Pract Diabetel. 2014 May/June;33:6-11.
  • 12. Bell DSH. Metformin: A lifesaver for those with and without diabetes. PracticalDiabetology. 2016 March/April;35:16-17.
  • 13. Guilliford MC, Booth HP, Reddy M, et al. Effect of contemporary bariatric surgery procedures on Type 2 diabetes remission—A population- based matched cohort study. Obes Surg 2016 Feb 27. [Epub ahead of print.]
  • 14. Omotosho P, Mor A, Shantavasinkul PC, et al. Gastric bypass significantly improves quality of life in morbidly obese patients with type 2 diabetes. Surg Endosc 2016;28. [Epub ahead of print.]
  • 15. deOliveira LF, Tisott CG, Silvano DM, et al. Glycemic behavior in 48 hours postoperative period of patients with type 2 diabetes mel- litus and nondiabetic submitted to bariatric surgery. Arg Bras Cir Dig 2015;28:26-30.
  • 16. Hansen M, Lund MT, Jorgensen AL, et al. The effects of diet-and RYGB-induced weight loss on insulin sensitivity in obese oatients with and without Type 2 diabetes. Acta Diabetol2015;53:423-432.
  • 17. Yaska JP, vanRoon EN, de Boer A, et al. Remission of Type 2 diabetes mellitus in patients after different types of bariatric surgery: A population-based cohort study in the United Kingdom. JAMA Surgery 2015 Dec 1;150(12):1126-1133.
  • 18. Pappachan JM, Viswanath AK. Metabolic surgery: A paradigm shift in Type 2 diabetes management. World J Diabetes 2015 Dec 1;150(12)1126-1133.
  • 19. Warren JA, Ewing JA, Hale AL, et al. Cost-effectiveness of bariatric surgery: Increasing the economic viability of the most effective treatment for Type II Diabetes Mellitus. Am Surg2015;81:807-811.
  • 20. Argyropoulos G. Bariatric surgery: Prevalence, predictors, and mechanisms of diabetes remission. Curr Diab Rep 2015;15:15.
  • 21. Cummings DE. Surgery to treat diabetes vs lifestyle interventions. Obesity Week 2013.
  • 22. Fanin A, Benetti A, Ceriani V, et al. Bariatric surgery versus medications in the treatment of Type 2 diabetes. Minerva Endocrinol 2015;40:297-306.
  • 23. Hsu CC, Almulaifi A, Chen JC, et al. Effect of bariatric surgery vs medical treatment on Type 2 diabetes on patients with body mass index lower than 35: Five-year outcomes. JAMA Surgery 2015 Dec 1;150(12):1117-1124.
  • 24. Singh AK, Singh R, Kota SK. Bariatric surgery and diabetes remission: Who would have thought it? Indian J Endocrinol Metab 2015 Sept-Oct;19(5):563-576.
  • 25. Chen Y, Corsino L, Shantavasinkul PC, et al. Gastric bypass leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg 2016;263(6):1138-1142.
  • 26. Brethauer SA, Aminian A, Romero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with Type 2 diabetes mellitus. Ann Surg 2013;258: 628-637.
  • 27. Panunji S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care 2016;39:166-174.
  • 28. Grams J, Garvey WT. Weight loss and the prevention and treatment of Type 2 diabetes using lifestyle therapy, pharmacotherapy and bariatric surgery: Mechanisms of action. Curr Obes Rep 2015;4:287-302.
  • 29. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment and prevention of the disease of obesity: Reflections form a diabetes care editors’ expert forum. Diabetes Care 2015;38:1567-1582.
  • 30. Khanna V, Malin SK, Bena J, et al. Adults with long-duration Type 2 diabetes have blunted glycemic and B cell function improvement after bariatric surgery. Obesity 2015;23:523-256.
  • 31. Jukubowicz D, Wainstein J, Ahren B, et al. Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with Type 2 diabetes: A randomized clinical trial. Diabetes Care 2015;38:1820-1826.
  • 32. Seaman AM. Bariatric surgery edges out lifestyle changes for Type 2 diabetes. JAMA Surgery 2015.
  • 33. Courcoulas AP, Belle BH, Neiberg RH, et al. Three year outcomes of bariatric surgery vs lifestyle intervention for Type 2 diabetes mellitus treatment. JAMA Surgery 2015;150:931-940.
  • 34. Dogan K, Betzel B, Homan J, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslip- idemia in morbidly obese patients. Obes Surg2014;24:1835-1842.
  • 35. Xiong SW, Cao J, Liu XM, et al. Effect of modified Roux-en-Y gastric bypass surgery on GLP-1, GIP in patients with Type 2 diabetes mellitus. Gastroenterol Res Pract 2015;62:5196.
  • 36. Golomb J, Bendavid M, Glass A, et al. Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surgery 2015;150:1051-1057.
  • 37. Ashrafian H, Harling L, Toma T, et al. Type 1 diabetes mellitus and bariatric surgery: A systemic review and meta-analysis. Obes Surg 2015 Dec 22.
  • 38. Mahawar KK, De Alwis N, Carr WR, et al. Bariatric surgery in Type 1 diabetes mellitus: A systemic review. Obes Surg 2016;26:196-204.
  • 39. Markova M et al. Better blood glucose control found with high-protein diets from plant, animal sources. Endocrine Today, Nov 2015.
  • 40. Martinez-Gonzalez MA, de la Fuente-Arrillaga C, Nunez-Cordoba JM, et al. Adherence to Mediterranean diet and risk of developing diabetes: Prospective cohort study. BMJ 2005;336:1348-1351.
  • 41. Lacoppidan SA, Kyra C, Loft S, et al. Adherence to a healthy nordic food index is associated with lower risk of Type 2 diabetes—The Danish Diet, Cancer and Health Cohort Study. Nutrients 2015;7:8633-8644.
  • 42. Saudi J. The effect of bariatric surgeries on nonalcoholic fatty liver disease. Gastroenterol 2014 Sept-Oct; 20(5): 270-278.
  • 43. Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005;13:1180-1186.
  • 44. Feijo SG, Lima JM, Oliveira MA, et al. The spectrum of non alcoholic fatty liver disease in morbidly obese patients: Prevalence and associated risk factors. Acta Cir Bras 2013;28:788-793.
  • 45. Xanthakos SA, Jenkins TM, Kleiner DE, et al. High prevalence of non alcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology 2015;149:623-634.
  • 46. Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol 2014;27:164.
  • 47. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010;28:274-279.
  • 48. deAlmeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006;16:270-278.
  • 49. Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 2007;17:486-492.
  • 50. Cheron RG, Kaplan MM, Larsen PR. Physiological and pharmacological influences on thyroxine to 3,5,3-triiodothyronine conversion and nuclear 3,5,3-triiodothyronine binding in rat anterior pituitary. J Clin Invest 1979;64:1402-1414.
  • 51. Araujo RL, Andrade BM, da Silva ML, et al. Tissue specific deiodinase regulation during food restriction and low replacement dose of leptin in rats. Am J Physiol Endocrinol Metab 2009;296:E1157-1163.
  • 52. Leibel RL, Jirsch J. Diminished energy requirements in reduced-obese patients. Metabolism 1984;33:164-170.
  • 53. Wilson D. Evidence-Based Approach to Restoring Thyroid Health. Lady Lake, FL: Muskeegee Medical Publishing, 2014.
  • 54. Fontana L, Klein S, Holloszy JO, et al. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab 2006;91:3232-3235.
  • 55. Silva JE, Larsen PR. Hormonal regulation iodothyronine 5’-deiodinase in rat brown adipose tissue. Am J Physiol 251;E639-E643.
  • 56. Croxson MS, Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism. J Clin Endocrinol Metab 1977;44:167-174.
  • 57. Katzeff HL, Selgrad C. Impaired peripheral thyroid hormone metabolism in genetic obesity. Endocrinology 1993;132:989-995.
  • 58. Islam S., Yesmire S, Khan SA, et al. A comparative study of thyroid hormone levels in diabetic and non-diabetic patients. SE Asian J Trop Med Public Health 2008;39:913-916.
  • 59. Benvenga S, Cahnmann HJ, Robbins J. Characterization of thyroid hormone binding to apolipoprotein E: Localization of the binding site in the exon 3-coded domain. Endocrinology 1993;133:1300-1305.
  • 60. McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine 2012;42:252-265.
  • 61. McGrogan A, Seaman HE, Wright JW, et al. The incidence of autoimmune thyroid disease: A systematic review of the literature. Clin Endocrinol 2008;69:687-696.
  • 62. Delange F. The disorders induced by iodine deficiency. Thyroid 1994;4:107-128.
  • 63. Pizzulli A, Ranjbar A. Selenium deficiency and hypothyroidism: A new etiology in the differential diagnosis of hypothyroidism in children. Biol Trace Elem Res 2000;77:199-208.
  • 64. Watts DL. The nutritional relationship of the thyroid. J Orthomol Med 1989;4:165-169.
  • 65. Lips MA, Pyl H, van Klinken JB, et al. Roux-en-Y gastric bypass and calorie restriction induce comparable time-dependent effects on thyroid hormone function tests in obese female subjects. Eur J Endocrinol 2013 Aug 28;169(3):339-347.
  • 66. MacCuish A, Razvi S, Syed AA. Effect of weight loss after gastric bypass surgery on thyroid function in euthyroid people with morbid obesity. Clin Obes 2012 Feb;2(1-2):25-28.
  • 67. Alagna S, Cossu ML, Masala A, et al. Evaluation of serum leptin levels and thyroid function in morbidly obese patients treated with bariatric surgery. Eat Weight Dis 2003 Jun;8(2):95-99.
  • 68. Janssen IM, Homan J, Schijns W, et al. Subclinical hypothyroidism and its relation to obesity in patients before and after Roux-en Y gastric bypass. Surg Obes Relat Dis 2015 Nov-Dec;11(6):1257-63.
  • 69. Chikunguwo S, Brethauer S, Nirujogi V, et al. Influence of obesity and surgical weight loss on thyroid hormone levels. Surg Obes Relat Dis 2007 Nov-Dec;3(6):631-35.
  • 70. Fazylov R, Soto E, Cohen S, et al. Laaparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg 2008 Jun;18(6):644-647.
  • 71. Gkotsina M, Michalaki M, Mamali I, et al. Improved levothroxine pharmacokinetics after bariatric surgery. Thyroid 2013 Apr; 23(4):414-419.
  • 72. Vita R, Fallahi P, Antonelli A, et al. The administration of thyroxine as a soft gel capsule or liquid solution. Expert Opin Drug Deliv 2014 Jul; 11(7):1103-1111.
  • 73. Michalaki M, Volonakis S, Mamali I, et al. Dietary iodine absorption is not influenced by malabsorptive bariatric surgery. Obes Surg 2014 Nov;24(11):1921-1925.
  • 74. Abu-Ghanem Y, Inbar R, Tyomkin V, et al. Effect of sleeve gastrectomy on thyroid hormone levels. Obes Surg2015 Mar;25(3):452-456.
  • 75. Dunaif A, Chang J, Franks S, et al eds. In: Contemporary Endocrinology. Totowa, NJ: Humana Press, 2008, p. 217.
  • 76. Davies N. Polycystic ovary syndrome. Diabetes Self Management Feb 2016.
  • 77. Thatcher SS. PCOS the Hidden Epidemic. Indianapolis, IN: Perspectives Press, 2000, p. 156.
  • 78. Escobar-Morreale HF. Surgical management of metabolic dysfunction in PCOS. Steroids 2012 Mar 10;77(4):312-316.
  • 79. Ollila MM, Piltonen T, Puukka, et al. Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: Prospective cohort study. J Clin Endocrinol Metab 2016;101:739-747.
  • 80. Messinis IE, Messini CI, Anifandis G, et al. Polycystic ovaries and obesity. Best Pract Res Clin Obstet Gynaecol2015 May;29(4):479-488.
  • 81. Caserta D, Adducchio G, Picchia S, et al. Metabolic syndrome and polycystic ovary syndrome: An intriguing relationship. Gynecol Endocrinol 2014 Jun;30(6):397-402.
  • 82. Eid GM, McCloskey C, Titchner R, et al. Changes in hormones and biomarkers in polycystic ovarian syndrome treated with gastric bypass. Surg Obes Relat Dis 2014 Sept-Oct;10(5):787-791.
  • 83. Schiavo L, Scalera G, Barbarisi A. Sleeve gastrectomy to treat con- commitant polycystic ovary syndrome, insulin and leptin resistance in a 27-year morbidly obese woman unresponsive to insulin-sensitizing drugs: A 3-year follow-up. Int JSurg Case Rep 2015 Oct 21;17:36-38.
  • 84. Skubleny D, Switzer NJ, Gill RS, et al. The impact of bariatric surgery on polycystic ovary syndrome: A systematic review and meta-analysis. Obes Surg 2016 Jan;26(1):169-176.
  • 85. Barber TM, Dimitriadis GK, Andreou A, et al. Polycystic ovary syndrome: Insight into pathogenesis and a common association with insulin resistance. Clin Med (Lond) 2015 Dec;15(Suppl 6):S72-S76.
  • 86. Turkmen S, Andreen L, Cengiz Y. Effects of Roux-en-Y gastric bypass surgery on eating behavior and allopregnanolone levels in obese women with polycystic ovary syndrome. Gynecol Endocrinol 2015 Apr;31(4):301-305.
  • 87. Moran LJ, Brinkworth GD, Norman RJ. Dietary therapy in polycystic ovary syndrome. Semin ReprodMed2008 Jan;26:85-92.
  • 88. Subbiah MT. Nutrigenetics and nutraceuticals: The next wave riding on personalized medicine. TranslRes 2007 Feb;149(2):55-61.
  • 89. Frankel F. The Methylation Miracle. New York, NY: St. Martin’s Press, 1999.
  • 90. Miller R, Bowers B. MethylGenetic Nutrition Breaking the Genetic Code. Philadelphia, PA, Nov 7-8, 2015.
  • 91. Yin RX, Wu DF, Aung LH, et al. Several lipid-related gene polymorphisms interact with overweight/obesity to moderate blood pressure levels. Int J Mol Sci 2012;13(9):2062-2081.
  • 92. Yin RX, Wu DF, Miao L, et al. Several genetic polymorphisms interact with overweight/obesity in influence serum lipid levels. Cardiovasc Diabetol 2012 Oct 8; 11:123.
  • 93. Lewis SJ, Lawlor DA, Nordestgaard BG, et al. The methylenetetrahy- drofolate reductase C677T genotype and the risk of obesity in three large population-based cohorts. Eur J Endocrinol2008 Jul;159(1):35-40.
  • 94. Alghasham A, Settin AA, Ali A, et al. Association of MTHFR C677T and A1298C gene polymorphisms with hypertension. Int J Health Sci 2012 Jan;6(1):3-11.
  • 95. Koo HS, Lee HS, Hong YM. Methylenetetrahydrofolate reductase TT genotype as a predictor of cardiovascular risk in hypertensive adolescents. Pediatr Cardiol2008 Jan;29(1):136-141.
  • 96. Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and associated diseases. Eur J Med Genet 2015 Jan;58(1):1-10.
  • 97. Lunegova OS, Kerimkulova AS, Turdakmatov NB, et al. Association of C677T gene polymorphism of methylenetetra- hydrofolate reductase with insulin resistance among Kirghizes. Kardiologiia 2011;51:58-62.
  • 98. Tavakkoly Bazzaz J, Shojapoor M, et al. Methlenetetrahydrofolate reductase gene polymorphism in diabetes and obesity. Mol Biol Rep 2010 Jan;37(1):105-109.
  • 99. Frelut ML, Nicolas JP, Guilland JC, et al. Methylenetetrathydrofolate reductase 677 C^T polymorphism: A link between birth weight and insulin resistance in obese adolescents. Int JPediatr Obes. 2011;6:e312-e317.
  • 100. DiRenzo L, Marsella LT, Sarlo F, et al. C677T gene polymorphism of MTHFR and metabolic syndrome: Response to dietary intervention. J Transl Med 2014 Nov 29;12:329.
  • 101. Yarandi SS, Griffith DP, Sharma R, et al. Optic neuropathy, myelopathy, anemia, and neutropenia casued by acquired copper deficiency after gastric bypass surgery. J Clin Gastroenterol2014 Nov-Dec;48(10):862-865.
  • 102. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofo- late are not the same thing. Xenobiotica 2014 May;44(5):480-8.
<<   CONTENTS   >>

Related topics